If your patient’s primary payer drug claim is billed under medical benefits, you can request COAGADEX (Coagulation Factor X, Human) co-pay assistance using this portal. Eligible patients can receive up to $12,000 per year to cover their out of pocket expenses. Note: Nursing and supply costs that may be associated with the administration of the medication are not eligible for assistance through this program.
* Prior to enrolling in this Kedrion Biopharma Inc. program, participants are responsible for checking with their insurance carrier to confirm that their participation is not inconsistent with their insurance carrier’s requirements.
This program is subject to change or discontinuation by Kedrion Biopharma Inc. at any time, for any reason, and with or without prior notice. This portal is administered by Medmonk for the COAGADEX Co-Pay Support Program.
Indications for COAGADEX
COAGADEX, a plasma-derived blood coagulation factor X concentrate, is indicated in adults and children (aged 12 years and above) with hereditary factor X deficiency for:
Limitation of use
Perioperative management of bleeding in major surgery in patients with severe hereditary factor X deficiency has not been studied.
Important Safety Information
COAGADEX is contraindicated in patients with known hypersensitivity to any of the components of the product.
Allergic type hypersensitivity reactions, including anaphylaxis, are possible with COAGADEX. If symptoms occur, patients should discontinue use of the product immediately and contact their physician.
The formation of neutralizing antibodies (inhibitors) to factor X is a possible complication in the management of individuals with factor X deficiency. Carefully monitor patients taking COAGADEX for the development of inhibitors by appropriate clinical observations and laboratory tests.
COAGADEX is made from human plasma and may contain infectious agents, e.g. viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. No cases of transmission of viral diseases, vCJD or CJD, have been associated with the use of COAGADEX.
In clinical studies, the most common adverse reactions (frequency ≥5% of subjects) with COAGADEX were infusion site erythema, infusion site pain, fatigue and back pain.
Please see full prescribing information for Coagadex.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Coagadex®
is a registered trademark of
Kedrion Biopharma Inc.
Coagadex is manufactured by Bio Products Laboratory U.S.A., Inc.
and distributed by
Kedrion Biopharma Inc.
US/X/0319/0016